TriSalus Life Sciences, Inc. (TLSI)
4.97
-0.17
(-3.31%)
USD |
NASDAQ |
Sep 03, 15:33
TriSalus Life Sciences EPS Diluted (Quarterly) : -0.1576 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1576 |
| March 31, 2026 | 0.0294 |
| December 31, 2025 | -0.2082 |
| September 30, 2025 | -0.9586 |
| June 30, 2025 | -0.2736 |
| March 31, 2025 | -0.3886 |
| December 31, 2024 | -0.3953 |
| September 30, 2024 | -0.1208 |
| June 30, 2024 | -0.2147 |
| March 31, 2024 | -0.6006 |
| December 31, 2023 | -1.568 |
| September 30, 2023 | -0.1429 |
| Date | Value |
|---|---|
| June 30, 2023 | -0.6078 |
| March 31, 2023 | -0.5708 |
| December 31, 2022 | -75.01 |
| September 30, 2022 | -25.95 |
| June 30, 2022 | 0.0764 |
| March 31, 2022 | 0.0908 |
| December 31, 2021 | 0.0927 |
| September 30, 2021 | 0.0597 |
| June 30, 2021 | 0.0121 |
| March 31, 2021 | -0.0119 |
| September 30, 2020 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -9.187M |
| Revenue (Quarterly) | 11.41M |
| Total Expenses (Quarterly) | 20.59M |
| Enterprise Value | 304.09M |
| Gross Profit Margin (Quarterly) | 86.78% |
| Profit Margin (Quarterly) | -80.54% |
| Earnings Yield | -26.06% |
| Normalized Earnings Yield | -27.80 |